Orphan drugs for the treatment of hairy cell leukemia

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Orphan Drugs

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/21678707.2013.745793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia

  2012cited by this paper
• Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

  2012cited by this paper
• BRAF inhibition in refractory hairy-cell leukemia.

  2012cited by this paper
• Novel and emerging drugs for rarer chronic lymphoid leukaemias.

  2012cited by this paper
• Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

  2012cited by this paper
• Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

  2012cited by this paper
• Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.

  2012cited by this paper
• Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders

  2012cited by this paper
• Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment.

  2011cited by this paper
• Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

  2011cited by this paper
• High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia

  2011cited by this paper
• Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

  2011cited by this paper
• Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping

  2011cited by this paper
• Modern strategies for hairy cell leukemia.

  2011cited by this paper
• BRAF mutations in hairy-cell leukemia.

  2011cited by this paper
• Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.

  2011influential reference
• Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens

  2011cited by this paper
• Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

  2011cited by this paper
• Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia

  2011cited by this paper
• Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns

  2010cited by this paper
• Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

  2009cited by this paper
• Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.

  2009cited by this paper
• Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.

  2009cited by this paper
• VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

  2009cited by this paper
• Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

  2009cited by this paper
• Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.

  2009cited by this paper
• Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

  2009cited by this paper
• Hairy cell leukemia: treatment successes in the past 25 years.

  2008cited by this paper
• The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia

  2007cited by this paper
• [Treatment of hairy cell leukemia with cladribine].

  2007cited by this paper
• Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

  2006cited by this paper
• Immunotoxins in the treatment of refractory hairy cell leukemia.

  2006cited by this paper
• Immunophenotyping and differential diagnosis of hairy cell leukemia.

  2006cited by this paper
• Role of interferon‐alpha administration after 2‐deoxycoformycin in the treatment of hairy cell leukemia patients

  2006cited by this paper
• Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction

  2006cited by this paper
• Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.

  2005cited by this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005cited by this paper
• HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

  2005cited by this paper
• The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes.

  2004cited by this paper
• An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

  2004cited by this paper
• Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1).

  2004cited by this paper
• Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors

  2004cited by this paper
• Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

  2003cited by this paper
• Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

  2003cited by this paper
• Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.

  2003cited by this paper
• The variant form of hairy-cell leukaemia.

  2003cited by this paper
• The natural history and clinico-pathological features of the variant form of hairy cell leukemia

  2001cited by this paper
• Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

  2001cited by this paper
• Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

  2001cited by this paper
• European Organization for Research and Treatment of Cancer.

  2000cited by this paper
• Immunohistochemical Detection of Cyclin D1 Using Optimized Conditions Is Highly Specific for Mantle Cell Lymphoma and Hairy Cell Leukemia

  2000cited by this paper
• Deoxycoformycin in the treatment of patients with hairy cell leukemia

  2000cited by this paper
• Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.

  2000cited by this paper
• Commentary on and reprint of Bouroncle BA, Wiseman BK, Doan CA, Leukemic reticuloendotheliosis, in Blood (1958) 13:609–630

  2000cited by this paper
• Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

  1999cited by this paper
• Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.

  1999cited by this paper
• 2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland

  1999cited by this paper
• Long term outcome of patients with hairy cell leukemia treated with pentostatin

  1999cited by this paper
• Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.

  1998cited by this paper
• Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.

  1998cited by this paper
• Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

  1997cited by this paper
• Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey

  1997cited by this paper
• Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-α-resistant hairy cell leukemia: 7-year follow-up

  1997cited by this paper
• 2‐Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy

  1996cited by this paper
• Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

  1995influential reference
• Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B.

  1995cited by this paper
• Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.

  1994cited by this paper
• Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515.

  1994cited by this paper
• Long term results with 2'deoxycoformycin in hairy cell leukemia.

  1994cited by this paper
• The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.

  1994cited by this paper
• Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature.

  1993cited by this paper
• A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.

  1992cited by this paper
• Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).

  1992cited by this paper
• Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases

  1992cited by this paper
• Pentostatin induces durable remissions in hairy cell leukemia.

  1991cited by this paper
• Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.

  1990cited by this paper
• Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

  1990cited by this paper
• Pentostatin in hairy cell leukemia: treatment by the special exception mechanism.

  1989cited by this paper
• Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.

  1989cited by this paper
• Pentostatin in the treatment of advanced hairy cell leukemia.

  1989cited by this paper
• Hairy cell leukemia: follow-up after completion of alpha interferon treatment.

  1989cited by this paper
• Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.

  1988cited by this paper
• Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group.

  1988cited by this paper
• Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.

  1987cited by this paper
• Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.

  1987cited by this paper
• Hairy cell leukemia: a tumor of pre-plasma cells.

  1985cited by this paper
• Alpha interferon for induction of remission in hairy-cell leukemia.

  1984cited by this paper
• Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin).

  1984cited by this paper
• Hairy-cell leukaemia.

  1978cited by this paper
• Early splenectomy in lymphoproliferative disorders.

  1974cited by this paper
• Leukemic reticuloendotheliosis

  1974cited by this paper

• No citing papers are available for this paper.